Trade Pfizer ^PFE

Pfizer (PFE) Stock Gains Ground on Once-Monthly Obesity Drug Breakthrough

Pinebridge Investments LLC Acquires New Shares in Pfizer Inc. $PFE - Zolmax

Pfizer Inc. $PFE Shares Bought by Capital International Ltd. CA - Stock Observer

DB&C Advisors LLC Purchases Shares of 37,182 Pfizer Inc. $PFE - Stock Observer

433,331 Shares in Pfizer Inc. $PFE Acquired by Pinebridge Investments LLC - Daily Political

What to know about berobenatide, Pfizer's experimental obesity drug

Pfizer's Berobenatide GLP-1 Obesity Data Might Change The Case For Investing In Pfizer (PFE)

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Vise Technologies Inc. Raises Stock Holdings in Pfizer Inc. $PFE - Zolmax

Vise Technologies Inc. Acquires 63,386 Shares of Pfizer Inc. $PFE

WCG Wealth Advisors LLC Acquires 31,159 Shares of Pfizer Inc. $PFE - Daily Political

Pfizer CEO Albert Bourla reflects on leadership through Covid successes and post-pandemic challenges

Johnson & Johnson (JNJ) Gets a Buy from Guggenheim

Pharmaceutical Stocks To Consider - June 5th - Stock Observer

Pfizer (NYSE:PFE) Trading Up 1.4% - What's Next? - Daily Political

Prudential PLC Sells 88,665 Shares of Pfizer Inc. $PFE

How New Multi‑Tumor Oncology Data At Pfizer (PFE) Has Changed Its Investment Story

US companies disclose huge Irish tax payments

Pfizer's integrin β6 ADC advances intravesical therapy for NMIBC | BioWorld

New US corporation tax regulations could put Ireland in Trump's crosshairs

UBS Remains a Buy on Olema Pharmaceuticals (OLMA)

Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

Diamond Blackfan Anemia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 - DelveInsight | Novartis AG, AstraZeneca, Pfizer Inc., Sanofi, Merck KGaA

Pfizer (NYSE:PFE) Trading 1.4% Higher - What's Next?

Pfizer (PFE) Partners with Chai Discovery for AI-Driven Drug Development

Pfizer strikes $10.5 billion oncology deal with Chinese biotech

Natixis Advisors LLC Raises Position in Pfizer Inc. $PFE

One Capital Management LLC Cuts Position in Pfizer Inc. $PFE

Pfizer patents new PI3Kα mutant inhibitors | BioWorld

Pfizer (PFE) Valuation Check After Recent Share Price Pressure And Rebuilding Momentum

Cigarette smoking, e-cigarette use, and hypertension: a population-based cross-sectional study

3 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now

Top 5 High-Yield Dividend Stocks for Income Investors in 2026

Pfizer vs Merck: Chasing High Yield vs Higher Returns

Bank of New York Mellon Corp Raises Stake in Pfizer Inc. $PFE

Celcuity (CELC) Shares Plunge Over 20% Following Phase 3 Trial Data

Is Pfizer Inc. (PFE) Expanding Its Cancer Pipeline Through a Landmark Innovent Partnership?

Why Pfizer's Current Price May Be Too Cheap to Ignore

Pfizer CEO Albert Bourla on the company's obesity drug pipeline

Pfizer CEO Albert Bourla on the company's oncology focus

Pfizer's ASCO 2026 Cancer Results Test Oncology Focus And Valuation Story

Pfizer Unveils Innovative Cancer Treatment Elranatamab in India, ETPharma

Work or vacation? Why global health giants are flocking to Hainan - Chinadaily.com.cn

Large-scale molecular endotype discovery in synovial fluid reveals osteoarthritis as a single biological continuum

Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohort

Pfizer (NYSE:PFE) Stock Price Down 2.1% - Here's Why

Promising Pharmaceutical Stocks To Follow Now - June 1st - Zolmax

Company Website: https://www.pfizer.com NEW YORK -- (Busin

Pfizer Oncology Deal And Lung Cancer Data Reshape Valuation Debate

Centene Corporation (CNC) and Pfizer (PFE) Stand Out in Valuatio

3 Cash-Producing Stocks Worth Your Attention

Pfizer Inc. $PFE Shares Acquired by Nomura Asset Management Co. Ltd.

Nomura Asset Management Co. Ltd. Has $52.42 Million Position in Pfizer Inc. $PFE - Daily Political

Assessing Celcuity (CELC) Valuation As Investor Optimism And Conflicting Fair Value Views Intensify

SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

Innovent Biologics and Pfizer ink $10.5 B deal to develop innovative oncology medicines

Evaluating the Clinical and Humanistic Impact of a Self-Care and Minor Ailment Service (MAS)

What To Buy If Not AI? Top Goldman Trader Finds 'Scarcity' Elsewhere

Is Pfizer Stock a "Value Trap" or a Generational Opportunity? - AOL

Pfizer (PFE) Reports Promising Results from Breakwater Trial

Cohort 3 analysis from the Phase 3 BREAKWATER study showed a

Pfizer announces results from Cohort 3 on Bratovi with cetuximab, Folfiri

11 Most Undervalued Pharma Stocks to Invest In

Pfizer announces results from Phase 3 Talapro-3 study of Talzenna, Xtandi

How S&P 500 Giant Pfizer Is Tackling Hard-To-Treat Cancers - Yahoo News Canada

Savant Capital LLC Has $4.02 Million Holdings in Pfizer Inc. $PFE

How Is Pfizer's Stock Performance Compared to Other Healthcare Stocks?

Eurizon Capital SGR S.p.A. Acquires New Stake in Pfizer Inc. $PFE

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial

Business Wire Releases - Barchart.com

Why Wall Street Is Dead Wrong About This Popular Stock

Pfizer Inc. $PFE Shares Sold by Koss Olinger Consulting LLC

Norges Bank Purchases New Position in Pfizer Inc. $PFE

Fideuram Asset Management Ireland dac Purchases New Stake in Pfizer Inc. $PFE - Stock Observer

Pfizer's US$10.5b Oncology Deal With Innovent And What It Means For Valuation

Pfizer's $10.5 Billion Oncology Bet Sends Innovent Shares Surging

EMA Recommends COVID-19 Vaccines Targeting XFG Variant for 2026/2027

Pfizer (PFE) Reveals Promising Seven-Year Findings from CROWN Trial

Pfizer and I-Mab Forge $10.5 Billion Cancer Drug Development Partnership

Pfizer Expands Oncology Pipeline in $10.5B Innovent Deal

Pfizer (NYSE:PFE) Trading Up 1.5% - Here's Why - Daily Political

Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer | Morningstar

Pfizer Inc. $PFE Stake Increased by National Pension Service

Moors & Cabot Inc. Lowers Holdings in Pfizer Inc. $PFE

Fidelis Capital Partners LLC Has $1.55 Million Stock Holdings in Pfizer Inc. $PFE - Zolmax

Pfizer Enters Deal With Innovent Biologics To Co-Develop Oncology Medicines

Moors & Cabot Inc. Has $7.03 Million Stock Position in Pfizer Inc. $PFE - Stock Observer

Pfizer Inc. $PFE Shares Bought by National Pension Service - Stock Observer

Pfizer Inc. $PFE Shares Acquired by Ilmarinen Mutual Pension Insurance Co - Stock Observer

Innovent Biologics Surges After Signing Up to $10.5 Billion Deal With Pfizer | Morningstar

China's Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials

Innovent Biologics, Pfizer strike $10.5b partnership deal amid China biotech boom

Innovent, Pfizer partner on 12 early-stage cancer programs | BioWorld

US Economy on Stagflation Watch: Apollo Global Management's Outlook

AI Podcast: Fresh Insights on Fed Rate Cut Timing - News in a New Way

Trump Announces 25% Tariffs on Automobiles, Pharmaceuticals, and Semiconductors

Week Ahead: US And Canada Labour Markets Are In Focus, BoE Rate Decision

Stock price forecast: 4 S&P 500 Stocks for 2025

Week ahead: Apple leads big tech earnings, UK Budget and Nonfarm Payrolls

Week ahead: Apple earnings land as Fed seen holding rates

Trump's Sudden Russia Policy Shift: Rubio's Influence and Implications

Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty

September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations

Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge

Fund Managers Cautious in Q4: AI, Inflation, and Monetary Policy in Focus

US Government Shutdown Threatens October Inflation Data Release

US-EU Relations: Russia Sanctions Unite Despite Trade Tensions

BOJ Warns of Japan Stock Market Overheating, U.S. Trade Policy Risk